OUTLOOK THERAPEUTICS INC

Outlook Therapeutics’ CEO buys shares and warrants amid a steep decline, signaling confidence in LYTENAVA’s future launch and potential rebound.

Insider buy by Ghiath Sukhtian backs Outlook Therapeutics’ FDA‑approved LYTENAVA, a promising wet‑AMD therapy poised to lift a weak market cap and shift investor sentiment.

Insider buys spike: Sukhtian Ghiath buys 95k shares amid a 49% YTD decline, signaling potential upside for a volatile biopharma stock.

Insider buying surge at Outlook Therapeutics signals confidence amid a 200 % rally; insider purchases align with clinical milestones, reverse split, and future funding plans.

Insider buying by Ghiath M. signals confidence in Outlook Therapeutics, a biotech poised to capitalize on its biosimilar platform amid FDA milestones and competitive pressure. Click for analysis.

Insider buying spurs confidence in Outlook Therapeutics as FDA approves eye‑treatment appeal, driving shares 102% higher and raising prospects for a 2026 launch.